Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1680 • ACR Convergence 2024
Reporting Quality of Non-inferiority and Equivalence Rheumatoid Arthritis Randomized Clinical Trials: A Systematic Review
Osama Alalwan¹ and Majeed Haider², ¹Salmaniya Medical Complex, Bahrain, Bahrain, ²Salmaniya Medical Complex, Manama, Bahrain
Background/Purpose: The number of non-inferiority/equivalence randomized clinical trials (NI/EQ-RCTs) in the rheumatoid arthritis (RA) field has recently increased for various reasons. These designs require special…
Abstract Number: 1840 • ACR Convergence 2024
Synovial Resident Memory T Cell Formation During Inflammation Requires Cell Contact with Fibroblast-Like Synoviocytes
Yusuke Miyashita¹, Yang Yang¹, Madison Mangin¹, Maryrose Hahn², Kevin Wei³, Peter Nigrovic⁴ and Margaret Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Georgetown, MA, ³Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁴Boston Children's Hospital, Brookline, MA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by recurrent inflammation in the same joints, a feature termed joint-specific memory. We previously demonstrated…
Abstract Number: 1901 • ACR Convergence 2024
Venous Thromboembolism Risk Is Consistently Increased in People with Rheumatoid Arthritis Across Different Ages, Sexes and Obesity Status: United Kingdom Population Based Study
James Galloway¹, Victoria Basey², Michael Mclean², Simon de Lusignan³ and Maya H. Buch⁴, ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²Pfizer UK, Tadworth, United Kingdom, ³Royal College of General Practitioners Research and Surveillance Centre, Oxford, United Kingdom, ⁴Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Risk of venous thromboembolism (VTE) is increased in people with rheumatoid arthritis (RA) when compared to the general population, but the variation of this…
Abstract Number: 2034 • ACR Convergence 2024
Effectiveness and Tolerability of Tocilizumab in Systemic Autoimmune Rheumatic Disease Associated Intertistial Lung Disease
Anne Dupont¹, Clairelyne Dupin², Esther Ebstein¹, Marine Forien¹, Sébastien Ottaviani¹, Pierre Le Guen², Quentin Philippot², Raphaël Borie², Bruno Crestani³, Philippe Dieudé¹ and Pierre-Antoine Juge⁴, ¹Departement of Rheumatology, AP-HP, Bichat Hospital, Paris, France, ²National Reference Center for Rare Pulmonary Diseases, Department of Pulmonology, AP-HP, Bichat Hospital, Paris, France, ³National Reference Center for Rare Pulmonary Diseases, Department of Pulmonology, AP-HP, Bichat Hospital, Paris, Ile-de-France, France, ⁴Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA
Background/Purpose: Interstitial lung diseases (ILD) are severe manifestations of systemic autoimmune diseases (SARD) that are associated with an increased mortality. Although the primary endpoint was not…
Abstract Number: 2215 • ACR Convergence 2024
Treat (Depression to Reach)-to-Target in Rheumatoid Arthritis
Ozun Bayindir Tsechelidis¹, Ricardo Sabido-Sauri², Ummugulsum Gazel², Seyyid Bilal Acikgoz³, Sylvia Sangwa⁴, Catherine Ivory⁵, Elliot Hepworth² and Sibel Aydin⁶, ¹Ottawa University, Ottawa, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³University of Ottawa, Rheumatology, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵The Ottawa Hospital, Ottawa, ON, Canada, ⁶University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: Depression is a prevalent comorbidity in Rheumatoid Arthritis (RA), affecting up to 38.8% of individuals. Depression can profoundly affect physical well-being, including increased pain…
Abstract Number: 2232 • ACR Convergence 2024
Anti-RA33 Autoantibodies Are Unique, Sensitive Biomarkers for the Identification of Seronegative Rheumatoid Arthritis in a U.S. Cohort
Andrew Concoff¹, Touba Warsi², Sepehr Taghavi², Sudha Kumar², Abigail Patalinghug², Christine Schleif², Brittany Partain³, Joseph Ahearn⁴, Nicole Wilson⁵, Susan Manzi⁵, Veena Joy⁶ and Tyler O'Malley⁷, ¹Exagen, Inc., Los Angeles, CA, ²Exagen, Carlsbad, CA, ³Exagen, Boston, MA, ⁴Allegheny Health Network, Wexford, PA, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶ThermoFisher, Philadelphia, PA, ⁷Exagen, Vista, CA
Background/Purpose: Novel autoantibodies (Ab) capable of identifying unique subgroups of seronegative rheumatoid arthritis (SN-RA) while providing specificity for RA comparable to ACPA reflects an opportunity…
Abstract Number: 2249 • ACR Convergence 2024
Assessment of Interstitial Lung Disease in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A National Multicenter Observational Study from the MAJIK-SFR Registry
Felicien Triboulet¹, Pierre-Antoine Juge², Marie-Elise Truchetet³, Thao Pham⁴, nicolas Roux⁵, Rene-Marc Flipo⁶, Charles Leske⁷, christian roux⁸, Raphaele Seror⁹, Andre Basch¹⁰, OLIVIER BROCQ¹¹, Pascal Chazerain¹², Fabienne Coury-Lucas¹³, Richard Damade¹⁴, Emmanuelle Dernis¹⁵, Jacques-Eric Gottenberg¹⁶, Andre Ramon¹⁷, Adeline Ruyssen-Witrand¹⁸, Jean-Hugues Salmon¹⁹, Emilie Shipley²⁰, Anne Tournadre²¹, CLEMENT PRATI²², Philippe Dieudé²³ and Jérôme Avouac²⁴, and and MAJIK -SFR registry investigators, ¹Service de Rhumatologie, hôpital Cochin, Paris, France, ²Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, ³Bordeaux University Hospital, Bordeaux, France, ⁴Assistance Publique-Hôpitaux de Marseille, Marseille, France, ⁵5Service de Rhumatologie, hôpital Robert-Schuman, Université de Lorraine, Metz, France, ⁶Service de Rhumatologie, hôpital Roger-Salengro, Université de Lille, Lille, France, ⁷Service de Rhumatologie, centre hospitalier de Cholet, Université d’Angers, Cholet, France, ⁸rheumatology department, university Cote d'Azur, nice, France, ⁹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ¹⁰Service de Rhumatologie, clinique de l'Infirmerie Protestante, Lyon, France, ¹¹Service de Rhumatologie, centre hospitalier Princesse-Grâce, Monaco, Monaco, ¹²Service de Rhumatologie, groupe hospitalier Diaconnesses - Croix-Saint-Simon, Paris, France, ¹³Service de Rhumatologie, hôpital Lyon-Sud, Université Claude-Bernard Lyon I, Hospices Civils de Lyon, Lyon, France, ¹⁴Service de Rhumatologie, hôpital Louis-Pasteur, Université d’Orléans, Chartres, France, ¹⁵CH LE MANS, LE MANS, Pays de la Loire, France, ¹⁶Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ¹⁷Dijon University Hospital, Besançon, France, ¹⁸Toulouse University Hospital, Toulouse, France, ¹⁹Service de Rhumatologie, centre hospitalier universitaire de Reims, Université de Reims Champagne-Ardenne, Reims, France, ²⁰Service de Rhumatologie, centre hospitalier Dax-Côte d’Argent, Université de Bordeaux, Dax, France, ²¹Service de Rhumatologie, centre hospitalier universitaire de Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France, ²²Service de Rhumatologie, centre hospitalier régional universitaire Jean-Minjoz, Université de Franche-Comté, Besançon, France, ²³Departement of Rheumatology, AP-HP, Bichat Hospital, Paris, France, ²⁴Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: The available data on the impact of JAK inhibitors (JAKi) on rheumatoid arthritis-associated interstitial lung disease (RA-ILD) are currently limited. This study aimed to…
Abstract Number: 2269 • ACR Convergence 2024
Adalimumab Dose Reduction Using Therapeutic Drug Monitoring to Manage Low Disease Activity in Rheumatoid Arthritis: A Single-Blind, Non-Inferiority, Randomized Clinical Trial
Sadaf Atiqi¹, Maike Wientjes², Maureen Leeuw³, Laura Boekel⁴, Femke Hooijberg¹, Floris Loeff⁵, Charlotte Krieckaert¹, Annick De Vries⁵, Michael Nurmohamed⁶, Theo Rispens⁵, Maarten Boers⁷, Bart van den Bemt⁸, Alfons den Broeder² and Gertjan Wolbink⁹, ¹Reade, Amsterdam, Netherlands, ²Sint Maartenskliniek, Ubbergen, Netherlands, ³Reade, Zeist, Netherlands, ⁴Vrije Universiteit Amsterdam, Amsterdam, Netherlands, ⁵Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁶Reade and Amsterdam UMC, Kortenhoef, Netherlands, ⁷Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ⁸Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands, ⁹Reade and Sanquin Diagnostic Services, Amsterdam, Netherlands
Background/Purpose: The latest European and American recommendations support tapering of biological DMARDs (bDMARDs) in patients with persistent remission or low disease activity. Most clinicians use…
Abstract Number: 2286 • ACR Convergence 2024
Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials
Josef Smolen¹, Gerd Burmester², Yoshiya Tanaka³, Tsutomu Takeuchi⁴, Jeffrey Curtis⁵, Ted Mikuls⁶, Clementina López Medina⁷, Peter C. Taylor⁸, Nicola Tilt⁹, Bernard Lauwerys¹⁰, Baran Ufuktepe¹¹ and Thomas Huizinga¹², ¹Medical University of Vienna, Vienna, Austria, ²Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁴Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁵The University of Alabama at Birmingham, Birmingham, AL, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Reina Sofia University Hospital, Cordoba, Spain, ⁸University of Oxford, Oxford, United Kingdom, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Istanbul, Turkey, ¹²Department of Rheumatology, Leiden University, Leiden, Netherlands
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), including those treated with disease-modifying antirheumatic drugs, high rheumatoid factor (RF) levels are a poor prognostic factor,…
Abstract Number: 2596 • ACR Convergence 2024
Clock Gene Bmal1 Contributes to Inflammation via Phosphorylation of NF-κB/p65 in RA-FLS
Hikari Tsukamoto¹, Kenta Kaneshiro¹, Kohsuke Yoshida¹, Koji Tateishi², Yasuhiro Terashima², Nao Shibanuma³, Yoshitada Sakai⁴ and Akira Hashiramoto¹, ¹Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan, ²Hakuhokai Kakogawa Hospital, Kakogawa, Hyogo, Japan, ³Kobe Kaisei Hospital, Kobe, Hyogo, Japan, ⁴Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
Background/Purpose: Inflammatory cytokines such as TNF-α, IL-6, and IFN-γ show their peaks at midnight in sera of patients with rheumatoid arthritis (RA), which is thought…
Abstract Number: PP03 • ACR Convergence 2024
How Completing a Systematic Literature Review Improved How I Research My Own Rheumatoid Arthritis and Comorbidities
Shelley Fritz, Global Healthy Living Foundation, Kalaheo, HI
Background/Purpose: Twelve years ago, I was diagnosed with rheumatoid arthritis (RA). Initially, I was hopeful that the first biologic DMARD would slow the disease and…
Abstract Number: 0034 • ACR Convergence 2024
Arthritogenic Subdoligranulum (S. Dido 7) Is Increased in Individuals At-Risk for and with Early RA and Decreases over Time During Development of Inflammatory Arthritis
Lyndsey Cole¹, Sucai Liu², Brendan Allen², Marie Feser³, Kristen Demoruelle⁴, Kevin Deane⁵, Michael Holers³ and Kristine Kuhn⁶, ¹University of Colorado School of Medicine, Centennial, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴University of Colorado Anschutz Medical Campus, Golden, CO, ⁵University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁶University of Colorado, Aurora, CO
Background/Purpose: Subdoligranulum didolesgii, S. dido 7, is present in a subset of individuals who are at-risk for RA (termed ‘ARI’) and who have clinical RA,…
Abstract Number: 0051 • ACR Convergence 2024
Impact of Tight Junction Proteins on Inflammatory Processes and Microbial Imbalance in Rheumatoid Arthritis
Arkaitz Mucientes¹, jose Manuel Lisbona-Montañez², Patricia Ruiz-Limón³, Sara Manrique-Arija⁴, Aimara García-Studer⁴, Fernando Ortiz-Márquez⁴, Natalia Mena Vázquez⁵ and Antonio Fernández-Nebro⁶, ¹IBIMA Plataforma BIONAND, Malaga, Andalucia, Spain, ²University of Malaga, Malaga, Andalucia, Spain, ³IBIMA, Instituto de Biomedicina de Málaga, Cordoba, Spain, ⁴Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, ⁵IBIMA, Málaga, Andalucia, Spain, ⁶Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain
Background/Purpose: The etiology of Rheumatoid Arthritis (RA) is not fully understood. Recent studies point to intestinal permeability as an important factor in the establishment and…
Abstract Number: 0087 • ACR Convergence 2024
SYNCAR: An Engineered IL-2/IL-2R-system That Selectively Enhances CD19 CAR T Cells to Deplete B Cells and Provide Therapeutic Benefit in SLE and RA Mouse Models Without Lymphodepletion
Ethan Jung¹, Marie semana¹, Ivan Cheng¹, Helena Silva¹, Sandro Vivona¹, Somya Singh¹, Michele Bauer¹, Mohammed Ali¹, Henry Rosas¹, Woei Chang¹, Deepti Rokkam¹, Patrick Lupardus¹, Martin Oft¹ and Paul-Joseph Aspuria², ¹Synthekine, Menlo Park, ²Sythekine, Menlo Park, CA
Background/Purpose: CD19 CAR-T therapy has demonstrated efficacy in autoimmune (AI) diseases like systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing its potential beyond oncology.…
Abstract Number: 0202 • ACR Convergence 2024
Survival in Patients with Rheumatoid Arthritis and Early-Stage Colorectal, Lung, or Prostate Cancer Receiving Tumor Necrosis Factor Alpha Inhibitors
Maria Suarez-Almazor¹, Juan Ruiz², Xiudong Lei¹, Hui Zhao¹, Suja Rajan³, Heather Lin¹ and Sharon Giordano¹, ¹MD Anderson Cancer Center, Houston, TX, ²MD Anderson, Houston, TX, ³The University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: There is concern about the use of tumor necrosis factor inhibitors (TNFi) in patients with early cancer given their immunosuppressant effects. Few studies have…

« Previous Page
1
…
7
8
9
10
11
…
188
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].